Ad
related to: fda approved kidney cancer treatment
Search results
Results from the WOW.Com Content Network
Sorafenib, sold under the brand name Nexavar, [3] is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. [2] It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer ...
US FDA approves Merck's drug for kidney cancer December 14, 2023 at 2:51 PM (Reuters) -The U.S. Food and Drug Administration on Thursday approved Merck's drug belzutifan for a type of kidney cancer.
Everolimus is approved for various conditions: Advanced kidney cancer (US FDA approved in March 2009) [15] Prevention of organ rejection after renal transplant(US FDA April 2010) [16] Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) in patients who are not suitable for surgical intervention (US FDA October 2010 ...
The FDA grants Merck's (MRK) NDA for belzutifan priority review status to treat von Hippel-Lindau disease-associated renal-cell carcinoma. Merck (MRK) VHL-Linked Kidney Cancer Drug Gets FDA ...
(Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo. Opdivo is part of a class of ...
[13] [14] The capsule form was approved in the European Union for the same purpose in 2014. [11] In April 2016, the FDA granted approval for marketing the tablet formulation (Cabometyx) as a second line treatment for kidney cancer [15] [16] and the same was approved in the European Union in September of that year. [12]
The FDA's outside advisers, however, recommended Xphozah's approval last year as a single therapy or alongside existing treatment for treating high blood phosphate levels in dialysis patients.
Ad
related to: fda approved kidney cancer treatment